Theragnostics inks licensing deal for one-step PET radiopharmaceuticals

Author : Pankaj Singh | Published Date : 2021-09-23 

Theragnostics, a company that provides targeted cancer medicine through molecular radiotherapy, has announced to have signed a global licensing agreement with Novartis-owned Advanced Accelerator Applications (AAA). The agreement will allow AAA to develop and commercialize Gallium-68 (Ga-68) one-step PET radiopharmaceuticals.

Under the terms of the deal, Theragnostics will receive an upfront fee as well as future royalties on sales of newly developed products. AAA will become the owner of exclusive rights for the commercialization of radiopharmaceuticals developed under the licensed patent.

Notably, the formulation of Ga-68 radiopharmaceuticals has always involved a multi-step approach, which resulted in a lower volume of patient doses produced. Theragnostics' new Ga-68 technology platform facilitates the production of the radiopharmaceutical in a sole multi-dose vial using a one-step procedure.

Chief Executive Officer at Theragnostics, Greg Mullen, was quoted saying that the company aims to develop targeted radionuclide therapies and innovative diagnostic imaging agents to boost treatment methods for a wide range of cancers.

He further added that the agreement with AAA will help in accelerating the development of Theragnostics’ radionuclide therapy, while also offering several new treatment options for patients suffering from various types of cancers.

Commenting on the significance of PET imaging, Ken Herrmann, Board Member at Theragnostics, stated that promising data for radioligand therapy in prostate cancer is likely to bolster the market demand for PSMA PET imaging. Theragnostics and AAA will now be able to reap the benefits of synergy and capture this burgeoning demand.

Founded in 2015, Theragnostics is a clinical-stage pharma company that develops precision oncology solutions for targeted radionuclide therapeutics and diagnostic imaging agents. The company has concluded several proof-of-concept phase I and II trials ranging across various radionuclide diagnostics and targeted therapies and is in the process of acquiring FDA approval for a radionuclide generic.

Source Credits –


About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Klarna partners with Stripe to revolutionize retail shopping experience

Published Date: 2021-10-27         Author: Pankaj Singh

Klarna, a leading worldwide retail bank, payments, and shopping service has announced a strategic alliance with Stripe to give a better shopping experience to retail consumers. Even the retailers who are using Stripe can now use Klarna as the preferred payment option to streamline the checkout ... Read More

Calyx bags 5-year data management contract with top 10 pharma firms

Published Date: 2021-10-26         Author: Pankaj Singh

Calyx’s industry-leading RIM (Regulatory Information Management) system has reportedly been selected by the world’s top 10 pharma companies for critical submissions of clinical development data to global regulators through 2026. The five-year contract signed by the top 10 companies wi... Read More

FPT Software, IGPI join hands to digitally transform Southeast Asia

Published Date: 2021-10-25         Author: Pankaj Singh

Vietnam’s FPT Software recently announced to have partnered with Industrial Growth Platform Pte. Ltd. (IGPI Singapore) to boost digital transformation (DX) for governments, institutions, corporates, and other relevant organizations in Southeast Asia. FPT Software and IGPI Singapore, under t... Read More

© 2021 Fractovia. All Rights Reserved